Myriad Genetics Inc. (MYGN)

30.29
NASDAQ : Health Technology
Prev Close 29.82
Day Low/High 29.84 / 30.56
52 Wk Low/High 22.04 / 48.40
Avg Volume 1.38M
Exchange NASDAQ
Shares Outstanding 73.87M
Market Cap 2.20B
EPS 0.10
P/E Ratio 497.00
Div & Yield N.A. (N.A)

Latest News

Myriad Genetics Investors: Filing Deadline In MYGN Class Action - Contact Lieff Cabraser

Myriad Genetics Investors: Filing Deadline In MYGN Class Action - Contact Lieff Cabraser

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that securities fraud class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Myriad Genetics, Inc.

Myriad Genetics To Present Five Studies At The 2019 American Society Of Human Genetics Annual Meeting

Myriad Genetics To Present Five Studies At The 2019 American Society Of Human Genetics Annual Meeting

SALT LAKE CITY, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

ROSEN, A LEADING LAW FIRM, Reminds Myriad Genetics, Inc. Investors Of Important Deadline In Securities Class Action - MYGN

ROSEN, A LEADING LAW FIRM, Reminds Myriad Genetics, Inc. Investors Of Important Deadline In Securities Class Action - MYGN

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Myriad Genetics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces That A Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. And Encourages Investors To Contact The Firm

INVESTOR ALERT: Kirby McInerney LLP Announces That A Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. And Encourages Investors To Contact The Firm

The law firm of Kirby McInerney LLP is announcing that a class action lawsuit has been filed in the U.

MYGN CLASS ACTION DEADLINE: Bernstein Liebhard LLP Announces The Filing Of A Securities Class Action Against Myriad Genetics

MYGN CLASS ACTION DEADLINE: Bernstein Liebhard LLP Announces The Filing Of A Securities Class Action Against Myriad Genetics

NEW YORK, Oct. 1, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of shareholders of Myriad Genetics ("Myriad" or the "Company")...

MYGN Loss Alert: Hagens Berman Notifies Investors In Myriad Genetics (MYGN) Of Securities Fraud Lawsuit

MYGN Loss Alert: Hagens Berman Notifies Investors In Myriad Genetics (MYGN) Of Securities Fraud Lawsuit

Class-action law firm urges MYGN investors who have suffered losses of 50K+ to learn their shareholder rights

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Myriad Genetics, Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - MYGN

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Myriad Genetics, Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - MYGN

NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Myriad Genetics, Inc.

MYGN LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN

MYGN LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Myriad Genetics, Inc.

Myriad Genetics Expands Board Of Directors With Two Additional Members

Myriad Genetics Expands Board Of Directors With Two Additional Members

Colleen F. Reitan and Lee N. Newcomer, M.D., Elected to Myriad's Board of Directors

Myriad Announces Research Collaboration With University Of Leeds

Myriad Announces Research Collaboration With University Of Leeds

Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer

Prolaris® Test Identifies Men With Prostate Cancer Who Can Safely Defer Treatment

Prolaris® Test Identifies Men With Prostate Cancer Who Can Safely Defer Treatment

65 Percent of Patients Remained on Active Surveillance for More than Four Years

Myriad Genetics To Present At The 2019 Morgan Stanley Global Healthcare Conference

Myriad Genetics To Present At The 2019 Morgan Stanley Global Healthcare Conference

SALT LAKE CITY, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Myriad Genetics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Myriad Genetics, Inc.

The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Myriad Genetics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Myriad Genetics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Myriad Genetics, Inc.

Myriad Applauds The U.S. Preventive Services Task Force Recommendation On BRCA-Related Cancer Prevention

Myriad Applauds The U.S. Preventive Services Task Force Recommendation On BRCA-Related Cancer Prevention

More Women May Benefit from Hereditary Cancer Risk Assessment and Genetic Testing

SHAREHOLDER ALERT: Investigation Of Myriad Genetics Announced By Holzer & Holzer, LLC

SHAREHOLDER ALERT: Investigation Of Myriad Genetics Announced By Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether certain statements made by Myriad Genetics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Myriad Genetics, Inc. - MYGN

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Myriad Genetics, Inc. - MYGN

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Myriad Genetics, Inc.

Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm

Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm

SAN FRANCISCO, Aug. 19, 2019 /PRNewswire/ -- Hagens Berman notifies investors in Myriad Genetics, Inc.

Investor Alert: Kaplan Fox Investigates Myriad Genetics, Inc.

Investor Alert: Kaplan Fox Investigates Myriad Genetics, Inc.

NEW YORK, Aug. 16, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.

Myriad Genetics Sinks on Fourth-Quarter Earnings and Revenue Miss

Myriad Genetics Sinks on Fourth-Quarter Earnings and Revenue Miss

Myriad Genetics tumbles after missing Wall Street's fiscal fourth-quarter earnings and revenue expectations.

Myriad Genetics Reports Fiscal Fourth-Quarter And Full-Year 2019 Financial Results

Myriad Genetics Reports Fiscal Fourth-Quarter And Full-Year 2019 Financial Results

Total Fourth-Quarter Revenues of $215.4 Million Fourth-Quarter Diluted EPS of ($0.

Myriad To Announce Fiscal Fourth-Quarter 2019 Financial Results On August 13, 2019

Myriad To Announce Fiscal Fourth-Quarter 2019 Financial Results On August 13, 2019

SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

Notable Thursday Option Activity: MYGN, GPRE, SNDX

Notable Thursday Option Activity: MYGN, GPRE, SNDX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Myriad Genetics, Inc. , where a total volume of 4,388 contracts has been traded thus far today, a contract volume which is representative of approximately 438,800 underlying shares (given that every 1 contract represents 100 underlying shares).

First Week Of MYGN January 2019 Options Trading

First Week Of MYGN January 2019 Options Trading

Investors in Myriad Genetics, Inc. saw new options begin trading this week, for the January 2019 expiration.

TheStreet Quant Rating: C (Hold)